ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Apr 11, 2023 13:58 JST
Source:
Essex Bio-Technology Limited
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China
HONG KONG, Apr 11, 2023 - (ACN Newswire) - Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. ("Gunze Shenzhen"), a wholly-owned subsidiary of Gunze Limited ("Gunze") in Japan, for PELNAC Absorbable Dressing ("PELNAC"), for a product manufactured by Gunze. Pursuant to the Agency Agreement, Essex Medipharma will be the exclusive agent of PELNAC in Mainland China for a period of 5 years, starting from 2023 to 2027.
PELNAC, the world's leading artificial dermis product, consists of a collagen sponge layer, which provides a scaffold for cellular invasion and capillary growth, and a silicone film layer, which is reinforced with non-adhesive gauze. It is suitable for full skin defects: (1) Full-thickness burns, (2) Traumatic skin defect wounds, (3) Skin defects after tumor or nevus removal, (4) Sites of skin flap extraction. PELNAC is not only available in Mainland China and Japan, but has also obtained the CE marking in the EU and FDA approval in the US.
PELNAC works well with Essex's bFGF-formulated products, the combination of the two products has a synergistic effect that would accelerate the vascularization and improve the viability rate in wound repair and healing.
The Group believes that with its strong marketing system and extensive distribution network, this cooperation will accelerate the market expansion of PELNAC in Mainland China and will further strengthen the Group's development in the field of wound healing for the clinical needs of more patients.
About Gunze Shenzhen
Gunze Medical Devices (Shenzhen) Limited was established in 2010 as a wholly owned subsidiary of Gunze Limited in China, focusing on the development, production and sales of regenerative medicine, and is responsible for the registration, marketing and after-sales management of Gunze Limited's absorbable medical materials in China. Its main products include absorbable dressing, PLLA bioabsorbable bone fixation devices, absorbable reinforcement felt and absorbable artificial dura mater, which are widely used in various departments such as thoracic surgery, orthopedics, burn surgery and neurosurgery.
About Essex
Essex Bio-Technology Limited is a biopharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun (Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wound healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,900 hospitals and managed directly by its 43 regional sales offices in China. Leveraging its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
Media Enquiry:
Strategic Financial Relations Limited (Website:
http://www.sprg.com.hk
)
Shelly Cheng +852 2864 4857
shelly.cheng@sprg.com.hk
Yan Li +852 2114 4320
yan.li@sprg.com.hk
June Tuo +852 2864 4848
june.tuo@sprg.com.hk
Angela Shen +852 2864 4870
angela.shen@sprg.com.hk
Media:
media@essex.com.cn
Investor Enquiry:
Investor Relations:
investors@essex.com.cn
Source: Essex Bio-Technology Limited
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
Honda and IBM sign Memorandum of Understanding to Explore Long-term Joint Research and Development of Semiconductor Chip and Software Technologies for Future Software-Defined Vehicles
May 15, 2024 14:30 JST
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15, 2024 11:19 JST
SMEIC Proposes to Acquire Shanghai Prime: A Catalyst for Developing a New Dual-Wheel Driver Pattern
May 14, 2024 21:54 JST
DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot
May 14, 2024 11:02 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
May 13, 2024 18:32 JST
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 17:06 JST
Ogier and TOYOTA GAZOO Racing triumph again
May 13, 2024 14:36 JST
Spa points haul for TOYOTA GAZOO Racing
May 13, 2024 13:56 JST
DOCOMO to Launch NTT DOCOMO GLOBAL for Global Expansion
May 10, 2024 18:13 JST
Release of "Fugaku-LLM" - a large language model trained on the supercomputer "Fugaku"
May 10, 2024 12:20 JST
Paltalk, Inc. Reports Slight Increase in Revenue and 33% Reduction in Net Loss for First Quarter 2024
May 09, 2024 20:39 JST
Cordlife Accelerates Lab and Technical Staff Recruitment to Rebuild Foundation and Strengthen Core Processes in Singapore
May 09, 2024 19:00 JST
Honda Opens New R&D Facility in Bengaluru to Accelerate Electrification in India
May 09, 2024 14:13 JST
Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planning
May 09, 2024 10:41 JST
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
May 08, 2024 14:27 JST
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers
May 08, 2024 12:00 JST
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement
May 08, 2024 10:24 JST
ServiceNow and Fujitsu announce strategic commitment to launch innovative cross-industry solutions
May 08, 2024 08:52 JST
More Latest Release >>
Related Release
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
March 18 2024 21:30 JST
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
August 16 2023 19:06 JST
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
July 26 2023 18:58 JST
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
April 14 2023 17:18 JST
Essex Bio-Technology Announces 2022 Annual Financial Results
March 08 2023 20:28 JST
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
February 22 2023 18:48 JST
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
February 10 2023 21:06 JST
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech
October 13 2022 22:40 JST
Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022"
August 16 2022 09:00 JST
Essex Bio-Technology Announces 2021 Financial Results
March 22 2022 20:12 JST
More Press release >>